Fedratinib Completed Phase 1 Trials for Hepatic Impairment Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01762462Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment